Increased efficacy was reported for amivantamab in combination with lazertinib, an EGFR-targeted tyrosine kinase inhibitor (TKI), compared to the established standard of care of osimertinib monotherapy in patients with untreated EGFR-mutated NSCLC in the MARIPOSA trial, and in combination with chemotherapy compared to chemotherapy alone after progression compared to osimertinib the MARIPOSA-2 trial [3,4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.